Real-world safety of nivolumab in patients with malignant pleural mesothelioma in Japan: post-marketing surveillance study
Japanese Journal of Clinical Oncology · 07.12.2024 · 54 (12) · 1321-1328
DOI: 10.1093/jjco/hyae119 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Japanese Journal of Clinical Oncology, online erschienen am 03.09.2024. Verfasst von Nobukazu Fujimoto und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Okayama Rosai Hospital, Okayama, Japan. Hauptthemen laut MEDLINE: Nivolumab, Mesothelioma, Malignant, Product Surveillance, Postmarketing, Pleural Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ono Pharmaceutical Co., Ltd, Bristol Myers Squibb.
Abstract (Originalsprache)
Objective
This post-marketing surveillance (PMS) was conducted to evaluate the incidence of adverse events with nivolumab in patients with unresectable, advanced or recurrent malignant pleural mesothelioma (MPM) that had progressed after first-line chemotherapy and to identify factors that potentially affected its safety in real-world clinical practice.
Methods
Patients who had not received nivolumab previously were registered between November 2018 and February 2021. Nivolumab was given intravenously 240 mg every 2 weeks or 480 mg every 4 weeks. Patients were followed up for 6 months after treatment initiation. Information on patient characteristics, treatment status, and adverse events was collected.
Results
This PMS enrolled 124 patients, involving 48 sites across Japan. At 6 months, nivolumab therapy was ongoing in 35.5% of patients (44/124) and had been discontinued in 64.5% (80/124). The overall incidence of treatment-related adverse events (TRAEs) was 40.3%; the incidence of Grade 3 or higher TRAEs was 12.9%. The pattern of TRAEs based on System Organ Class categories was generally consistent with those seen in the Japanese phase II MERIT study. The most common Grade 3 or higher TRAEs were interstitial lung disease (2.4%), lung disorder, and diarrhea (each 1.6%). The incidence of TRAEs was significantly higher in inpatients or patients who had good PS, high bodyweight, high body mass index, or autoimmune diseases than in those without these characteristics.
Conclusion
The post-marketing incidence of TRAEs with nivolumab in patients with MPM has been evaluated, and no new safety signals were identified compared to the phase II clinical trial in Japan.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Okayama Rosai Hospital, Okayama, Japan.
- Pharmacovigilance Division, Ono Pharmaceutical, Osaka, Japan.
- Department of Thoracic Oncology, National Cancer Center Hospital, Tokyo, Japan.
ORCID-Profile: Nobukazu Fujimoto, Yuichiro Ohe
Förderung
- Ono Pharmaceutical Co., Ltd
- Bristol Myers Squibb
Zitieren
APA
Fujimoto, N., Akamatsu, A., Honda, C., Aoki, M., & Ohe, Y. (2024). Real-world safety of nivolumab in patients with malignant pleural mesothelioma in Japan: post-marketing surveillance study. Japanese Journal of Clinical Oncology, 54(12), 1321-1328. https://doi.org/10.1093/jjco/hyae119
Vancouver
Fujimoto N, Akamatsu A, Honda C, Aoki M, Ohe Y. Real-world safety of nivolumab in patients with malignant pleural mesothelioma in Japan: post-marketing surveillance study. Japanese Journal of Clinical Oncology. 2024;54(12):1321-1328. doi:10.1093/jjco/hyae119
BibTeX
@article{Fujimoto2024,
author = {Fujimoto, Nobukazu and Akamatsu, Ayumi and Honda, Chikara and Aoki, Miki and Ohe, Yuichiro},
title = {Real-world safety of nivolumab in patients with malignant pleural mesothelioma in Japan: post-marketing surveillance study},
journal = {Japanese Journal of Clinical Oncology},
year = {2024},
volume = {54},
number = {12},
pages = {1321--1328},
doi = {10.1093/jjco/hyae119}
}
EUVIMED